Families USA and 17 other consumer groups sent a letter to the House of Representatives urging passage of surprise bill legislation that fully protects consumers while preventing inflation in health care costs.
In this June 12, 2019 testimony before the U.S. House of Representatives Energy and Commerce Subcommittee on Health, Claire McAndrew, Director of Campaigns and Partnerships at Families USA, breaks down the problem with surprise medical bills and potential solutions under consideration by the committee.
In this testimony before the U.S. House of Representatives Energy and Commerce Committee on May 21, 2019, Frederick Isasi, Executive Director of Families USA, breaks down the problem with high drug prices and potential solutions under consideration by the committee. While high drug prices are a source of seemingly constant debate in Washington, D.C., for millions of America’s families, they are a painful and burdensome reality and can impact the basic necessities of life.
Drug companies consistently set high prices, which forces families to make impossible choices between their health care and other basic needs. Drug companies set exorbitant prices by design to maximize their profits, while making misleading claims that high prices simply fund innovative new drugs. Despite this gaming, our political system makes it easy for drug companies to continue exploitative pricing. This piece explains how our current drug pricing system leads to unaffordable prescription drugs, and ultimately harms people’s health.
Families USA, in partnership with American Academy of Family Physicians, American Benefits Council, American Federation of State, Country, and Municipal Employees, American Federation of Teachers, First Focus, and Pacific Business Group on Health, is launching Consumers First: The Alliance to Make the Health Care System Work for Everyone.
Families USA submitted the attached letter to U.S. House of Representatives Leadership in support of H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act.
Congressional committees have advanced initial measures to address prescription drug costs. However, their work to date has not focused on the significant policy changes needed to meaningfully lower drug prices. To address the drivers of excessive prescription drug prices in the United States, the Coalition for Fair Drug Prices urges Congress to enact meaningful policies that leverage the federal government’s power to negotiate drug prices.
Not measuring and paying for equity risks worsening disparities and it is a key missed opportunity for reducing disparities. This webinar discusses actionable opportunities at the state and federal level to measure and pay for equity.
Not measuring and paying for equity risks worsening disparities and it is a key missed opportunity for reducing disparities. This issue brief describes actionable opportunities at the state and federal level to measure and pay for equity.
This guide outlines model policies for states to consider to rein in drug prices in 2019 and beyond. Those discussed first most directly target drug prices and therefore are likely to have the greatest impact. This piece also cautions against prioritizing approaches to import drugs from Canada, as these policies are less likely to bring savings despite their public appeal.